Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA May Wait Until Late 2019 Before A Cures Hiring Enhancement Is Available

Executive Summary

Senior Biomedical Research Service expansion, used to attract elite scientists to federal service, may not be implemented until late 2019; FDA also may have a candidate for OND director.

Related Content

US FDA's Orphan Drug Designation Reviews Often Don't Include Regulatory Histories, GAO Says
CDER Recruitment Wins Begin Outnumbering Losses
US FDA's Ostroff, Twice An Acting Commissioner, Retiring Next Year
US FDA Appoints Another Orphan Products Development Office Head Amid Growth Expectations
The Two Towers: US FDA's HQ Expansion Plans Include Office High-Rises, New Conference Center
US FDA's Streamlined Hiring Pilot Restarts After Delay
Orphan, Combo, Pediatric Products Would See More Influence In Proposed US FDA Reorg
New OND Director Could Be Hired Within Six Months, Woodcock Says
US FDA's Acting Orphan Products Development Director Has Gene Therapy Background
New CDER No. 2 May Impact FDA's Safety Monitoring Aspirations





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts